Priming a vascular-selective cytokine response permits CD8+ T-cell entry into tumors
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Priming a vascular-selective cytokine response permits CD8+ T-cell entry into tumors
Authors
Keywords
-
Journal
Nature Communications
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-04-14
DOI
10.1038/s41467-023-37807-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop
- (2022) Yichao Hua et al. CANCER CELL
- Dual role of endothelial Myct1 in tumor angiogenesis and tumor immunity
- (2021) Ashraf Ul Kabir et al. Science Translational Medicine
- High endothelial venules (HEVs) in immunity, inflammation and cancer
- (2021) Lucas Blanchard et al. ANGIOGENESIS
- Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
- (2021) Zowi R. Huinen et al. Nature Reviews Clinical Oncology
- A single-cell and spatially resolved atlas of human breast cancers
- (2021) Sunny Z. Wu et al. NATURE GENETICS
- DNA hypomethylation leads to cGAS‐induced autoinflammation in the epidermis
- (2021) Mirjam A Beck et al. EMBO JOURNAL
- An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates
- (2020) Jermaine Goveia et al. CANCER CELL
- Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice
- (2020) Simone Ragusa et al. JOURNAL OF CLINICAL INVESTIGATION
- Endothelial sphingosine 1-phosphate receptors promote vascular normalization and antitumor therapy
- (2020) Andreane Cartier et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Remodeling of Metastatic Vasculature Reduces Lung Colonization and Sensitizes Overt Metastases to Immunotherapy
- (2020) Bo He et al. Cell Reports
- EO771, the first luminal B mammary cancer cell line from C57BL/6 mice
- (2020) Augustin Le Naour et al. Cancer Cell International
- Stromal cell diversity associated with immune evasion in human triple‐negative breast cancer
- (2020) Sunny Z Wu et al. EMBO JOURNAL
- Targeting the epigenetic regulation of antitumour immunity
- (2020) Simon J. Hogg et al. NATURE REVIEWS DRUG DISCOVERY
- Tumor-Derived cGAMP Regulates Activation of the Vasculature
- (2020) Marco Campisi et al. Frontiers in Immunology
- Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors
- (2019) Denarda Dangaj et al. CANCER CELL
- STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade
- (2019) Hannah Yang et al. JOURNAL OF CLINICAL INVESTIGATION
- Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance
- (2019) Dhanya K. Nambiar et al. JOURNAL OF CLINICAL INVESTIGATION
- Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy
- (2019) Abhishek S. Kashyap et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy
- (2018) Angela Rita Elia et al. CLINICAL CANCER RESEARCH
- Increased vessel perfusion predicts the efficacy of immune checkpoint blockade
- (2018) Xichen Zheng et al. JOURNAL OF CLINICAL INVESTIGATION
- DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer
- (2018) Na Luo et al. Nature Communications
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
- (2018) Livnat Jerby-Arnon et al. CELL
- Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
- (2018) Shunsuke Kitajima et al. Cancer Discovery
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- On-chip human microvasculature assay for visualization and quantification of tumor cell extravasation dynamics
- (2017) Michelle B Chen et al. Nature Protocols
- Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden
- (2017) Meredith L. Stone et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
- (2017) Martina Schmittnaegel et al. Science Translational Medicine
- Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
- (2017) Elizabeth Allen et al. Science Translational Medicine
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Differential Expression of Homing Receptor Ligands on Tumor-Associated Vasculature that Control CD8 Effector T-cell Entry
- (2017) Amber N. Woods et al. Cancer Immunology Research
- Endothelial Side Population Cells Contribute to Tumor Angiogenesis and Antiangiogenic Drug Resistance
- (2016) H. Naito et al. CANCER RESEARCH
- Functional Definition of Progenitors Versus Mature Endothelial Cells Reveals Key SoxF-Dependent Differentiation ProcessClinical Perspective
- (2016) Jatin Patel et al. CIRCULATION
- Dynamic Patterns of Clonal Evolution in Tumor Vasculature Underlie Alterations in Lymphocyte–Endothelial Recognition to Foster Tumor Immune Escape
- (2015) Daniel M. Corey et al. CANCER RESEARCH
- Tumor Endothelial Cells with Distinct Patterns of TGF -Driven Endothelial-to-Mesenchymal Transition
- (2015) L. Xiao et al. CANCER RESEARCH
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
- (2015) Katherine B. Chiappinelli et al. CELL
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints
- (2015) M. E. Mikucki et al. Nature Communications
- DNMT1 is essential for mammary and cancer stem cell maintenance and tumorigenesis
- (2015) Rajneesh Pathania et al. Nature Communications
- Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model
- (2015) L. Wang et al. Cancer Immunology Research
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis
- (2013) Rebecca S. Cook et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor Endothelial Cells
- (2013) A. C. Dudley Cold Spring Harbor Perspectives in Medicine
- Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry
- (2012) A. M. Mulligan et al. CLINICAL CANCER RESEARCH
- PKC isoforms interact with and phosphorylate DNMT1
- (2011) Geneviève Lavoie et al. BMC BIOLOGY
- Identification and characterization of a resident vascular stem/progenitor cell population in preexisting blood vessels
- (2011) Hisamichi Naito et al. EMBO JOURNAL
- DNMT1 maintains progenitor function in self-renewing somatic tissue
- (2010) George L. Sen et al. NATURE
- A methylation and phosphorylation switch between an adjacent lysine and serine determines human DNMT1 stability
- (2010) Pierre-Olivier Estève et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model
- (2009) X. Ma et al. MOLECULAR CANCER THERAPEUTICS
- Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
- (2007) Ronald J Buckanovich et al. NATURE MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started